• Progyny, Inc. recently announced Progyny Select, a fully insured, supplemental fertility and family-building plan aimed at small U.S. employers, alongside plans to seek stockholder approval in May 2026 to reduce several supermajority voting thresholds in its governing documents.
• This combination of a new product tailored to a large small-employer market and proposed governance changes could reshape both Progyny’s growth opportunities and shareholder influence over key corporate decisions.
• Next, we’ll examine how targeting small employers with Progyny Select may influence Progyny’s investment narrative and longer-term growth prospects.

Uncover the next big thing with 29 elite penny stocks that balance risk and reward.

Progyny Investment Narrative Recap

To own Progyny, you need to believe employer-funded fertility and family-building benefits can remain a priority even as companies watch costs and competition intensifies. The launch of Progyny Select for small employers and the planned shift from supermajority to simple-majority voting look directionally supportive of growth and shareholder influence, but they do not materially change the near term risks around employer benefit budgeting and rising competition from health plans and other fertility benefit providers.

Among recent developments, the proposed 2026 governance changes to eliminate several supermajority voting thresholds are most relevant here, as they sit alongside the new small-employer product launch. While these amendments would not directly affect revenue, they could make it easier for shareholders to influence future capital allocation, potential M&A, and board composition, all of which intersect with how Progyny pursues its growth catalysts and responds if competitive or regulatory pressures increase.

But against the promise of broader access to fertility benefits, investors should also weigh the risk that employer cost-cutting pressures could eventually...

Progyny's narrative projects $1.6 billion revenue and $112.9 million earnings by 2028. This requires 8.9% yearly revenue growth and about a $59.8 million earnings increase from $53.1 million today.

Uncover how Progyny's forecasts yield a $30.91 fair value, a 72% upside to its current price.

Exploring Other Perspectives

More optimistic analysts already expected Progyny to reach about US$1.8 billion in revenue and US$151 million in earnings, yet this new small employer push and governance shift could either reinforce that faster growth story or validate more cautious views that employer demand and benefit budgets are less predictable than those bullish forecasts suggest.

Explore 4 other fair value estimates on Progyny - why the stock might be worth just $26.00!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Progyny research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Progyny research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Progyny's overall financial health at a glance.

Looking For Alternative Opportunities?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• AI is about to change healthcare. These 35 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.